Sign in to see private stats on your profile page — or add photo, interests, videos, mentoring, etc.

    Jo Chien, MD

    TitleAssociate Professor
    SchoolUCSF School of Medicine
    DepartmentMedicine
    Address1600 Divisadero St.,MZ Bldg B
    San Francisco CA 94115
    Phone415-353-7070
    vCardDownload vCard

      Collapse Biography 
      Collapse Education and Training
      Harvard UniversityM.D.School of Medicine2003

      Collapse Overview 
      Collapse Overview
      Dr. A. Jo Chien specializes in breast cancer, with special expertise in tumors that are called HER2+ (human epidermal growth factor receptor 2), typically a more aggressive type of cancer. Her primary research interests include HER2+, breast cancer in young women, and fertility problems related to cancer treatment.

      Chien graduated from Harvard Medical School in 2003 and completed a residency in internal medicine at Massachusetts General Hospital in Boston. She was a fellow in the hematology and oncology at UCSF from 2006 to 2009. Chien received the Massachusetts Medical Society and Alliance Charitable Foundation International Health Grant in 2003, American Society of Clinical Oncology (ASCO) Young Investigator Award in 2008; ASCO Foundation Merit Award in 2008; and American Cancer Society Postdoctoral Fellowship in 2008. She has published numerous articles in medical journals related to her breast cancer research. Chien is a member of the American Society of Clinical Oncology and the American Association of Cancer Research. She is an assistant professor of medicine at UCSF.


      Collapse ORNG Applications 
      Collapse Websites
      Collapse In The News
      Collapse Clinical Trials
      Collapse Global Health

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Chien AJ, Cockerill A, Fancourt C, Schmidt E, Moasser MM, Rugo HS, Melisko ME, Ko AH, Kelley RK, Korn WM, Esserman LJ, Van't Veer L, Yau C, Wolf DM, Munster PN. A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies. Breast Cancer Res Treat. 2016 Feb; 155(3):521-30. PMID: 26875185.
        View in: PubMed
      2. Chien AJ, Duralde E, Hwang R, Tsung K, Kao CN, Rugo HS, Melisko ME, Esserman LJ, Munster PN, Cedars M, Kerlikowske K, McCulloch CE, Rosen MP. Association of tamoxifen use and ovarian function in patients with invasive or pre-invasive breast cancer. Breast Cancer Res Treat. 2015 Aug; 153(1):173-81. PMID: 26208485.
        View in: PubMed
      3. DeMichele A, Yee D, Berry DA, Albain KS, Benz CC, Boughey J, Buxton M, Chia SK, Chien AJ, Chui SY, Clark A, Edmiston K, Elias AD, Forero-Torres A, Haddad TC, Haley B, Haluska P, Hylton NM, Isaacs C, Kaplan H, Korde L, Leyland-Jones B, Liu MC, Melisko M, Minton SE, Moulder SL, Nanda R, Olopade OI, Paoloni M, Park JW, Parker BA, Perlmutter J, Petricoin EF, Rugo H, Symmans F, Tripathy D, Van't Veer LJ, Viscusi RK, Wallace A, Wolf D, Yau C, Esserman LJ. The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer. Clin Cancer Res. 2015 Jul 1; 21(13):2911-5. PMID: 25712686; PMCID: PMC4490043 [Available on 07/01/16].
      4. Chien AJ, Munster PN, Melisko ME, Rugo HS, Park JW, Goga A, Auerback G, Khanafshar E, Ordovas K, Koch KM, Moasser MM. Phase I dose-escalation study of 5-day intermittent oral lapatinib therapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer. J Clin Oncol. 2014 May 10; 32(14):1472-9. PMID: 24711549; PMCID: PMC4017711.
      5. DeMichele A, Berry DA, Zujewski J, Hunsberger S, Rubinstein L, Tomaszewski JE, Kelloff G, Perlmutter J, Buxton M, Lyandres J, Albain KS, Benz C, Chien AJ, Haluska P, Leyland-Jones B, Liu MC, Munster P, Olopade O, Park JW, Parker BA, Pusztai L, Tripathy D, Rugo H, Yee D, Esserman L. Developing safety criteria for introducing new agents into neoadjuvant trials. Clin Cancer Res. 2013 Jun 1; 19(11):2817-23. PMID: 23470967; PMCID: PMC4096560.
      6. Yee D, Haddad T, Albain K, Barker A, Benz C, Boughey J, Buxton M, Chien AJ, DeMichele A, Dilts D, Elias A, Haluska P, Hogarth M, Hu A, Hytlon N, Kaplan HG, Kelloff GG, Khan Q, Lang J, Leyland-Jones B, Liu M, Nanda R, Northfelt D, Olopade OI, Park J, Parker B, Parkinson D, Pearson-White S, Perlmutter J, Pusztai L, Symmans F, Rugo H, Tripathy D, Wallace A, Wholley D, Van't Veer L, Berry DA, Esserman L. Adaptive trials in the neoadjuvant setting: a model to safely tailor care while accelerating drug development. J Clin Oncol. 2012 Dec 20; 30(36):4584-6; author reply 4588-9. PMID: 23169510.
        View in: PubMed
      7. Chien AJ, Rugo HS. Emerging treatment options for the management of brain metastases in patients with HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2013 Jan; 137(1):1-12. PMID: 23143215; PMCID: PMC3528960.
      8. Bock M, Moore D, Hwang J, Shumay D, Lawson L, Hamolsky D, Esserman L, Rugo H, Chien AJ, Park J, Munster P, Melisko M. The impact of an electronic health questionnaire on symptom management and behavior reporting for breast cancer survivors. Breast Cancer Res Treat. 2012 Aug; 134(3):1327-35. PMID: 22798157.
        View in: PubMed
      9. Rugo HS, Chien AJ, Franco SX, Stopeck AT, Glencer A, Lahiri S, Arbushites MC, Scott J, Park JW, Hudis C, Nulsen B, Dickler MN. A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer. Breast Cancer Res Treat. 2012 Jul; 134(1):13-20. PMID: 22198412; PMCID: PMC3397213.
      10. Letourneau JM, Ebbel EE, Katz PP, Katz A, Ai WZ, Chien AJ, Melisko ME, Cedars MI, Rosen MP. Pretreatment fertility counseling and fertility preservation improve quality of life in reproductive age women with cancer. Cancer. 2012 Mar 15; 118(6):1710-7. PMID: 21887678; PMCID: PMC3235264.
      11. Letourneau JM, Ebbel EE, Katz PP, Oktay KH, McCulloch CE, Ai WZ, Chien AJ, Melisko ME, Cedars MI, Rosen MP. Acute ovarian failure underestimates age-specific reproductive impairment for young women undergoing chemotherapy for cancer. Cancer. 2012 Apr 1; 118(7):1933-9. PMID: 21850728; PMCID: PMC3220922.
      12. Chien AJ, Rugo HS. The cardiac safety of trastuzumab in the treatment of breast cancer. Expert Opin Drug Saf. 2010 Mar; 9(2):335-46. PMID: 20175700.
        View in: PubMed
      13. Chien AJ, Illi JA, Ko AH, Korn WM, Fong L, Chen LM, Kashani-Sabet M, Ryan CJ, Rosenberg JE, Dubey S, Small EJ, Jahan TM, Hylton NM, Yeh BM, Huang Y, Koch KM, Moasser MM. A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignancies. Clin Cancer Res. 2009 Sep 1; 15(17):5569-75. PMID: 19706807; PMCID: PMC3029022.
      14. Chien AJ, Moasser MM. Cellular mechanisms of resistance to anthracyclines and taxanes in cancer: intrinsic and acquired. Semin Oncol. 2008 Apr; 35(2 Suppl 2):S1-S14; quiz S39. PMID: 18410794.
        View in: PubMed
      Jo's Networks
      Related Concepts
      Derived automatically from this person's publications.
      _
      Co-Authors
      People in Profiles who have published with this person.
      _
      Related Authors
      People who share related concepts with this person.
      _
      Back to TOP